Clinically relevant content
A highly focused panel covering the actionable mutations in key oncogenes in the EGFR pathway.
Primary tumor or liquid biopsy
Developed for and validated on cfDNA as well as gDNA and FFPE giving you the option to profile primary tumors or liquid biopsies and matched samples.
Confidently call low frequency variants
Cell3 Target error suppression technology including unique molecular identifiers (UMIs), enables you to accurately call ultra-low frequency mutations down to 0.1% VAF.
Fast and affordable
Using a focused panel simplifies analysis and reduces costs making this a fast and affordable method of profiling variants in the EGFR pathway.
Focused coverage of EGFR pathway
We know that a fast and affordable panel for profiling pathways like the EGFR (Epidermal Growth Factor Receptor) pathway is important to you so the Cell3 Target: Actionable Mutation panel (EGFR) only enriches for actionable mutations in the most relevant oncogenes. It offers a simple, fast and cost-effective tool to enable early cancer detection, treatment selection and patient monitoring in cancers like non-small lung cancer.
Table 1: Gene content for Cell3 Target: Actionable Mutation panel
| Gene | Number of targets | Including coverage of: |
|---|---|---|
| BRAF | 2 | V600 |
| EGFR | 9 | G719, D761, T790, L858, L861, exon 19 indel, exon 20 insertion |
| KRAS | 3 | G12, G13, Q61, A416 |
| NRAS | 3 | G12, G13, Q61 |
Sensitive enough for liquid biopsy
Liquid biopsy offers a non-invasive method of detecting cancer early or monitoring cancer post chemotherapy or surgery, but it requires extremely sensitive analysis due to the small amounts of cell-free DNA (cfDNA) and even smaller amounts of circulating tumor DNA (ctDNA) present.
The error suppression technology of Nonacus Cell3 Target libraries includes unique molecular indexes (UMIs) and unique dual indexes (UDIs) for removal of both PCR and sequencing errors and index hopping events. This ensures that the Actionable Mutation panel (EGFR) will enable you to confidently call mutations down to 0.1% VAF and enables generation of sequencing libraries from as little as 1 ng of cfDNA input.
Table 2: No. of samples per flow cell to achieve 100x mean depth of coverage based on 2x100 bp library and maximum quoted sequencer output for Cell3 Target: Actionable Mutation panel.
| Product | Sequencer | Flow cell | Samples/flow cell | Average depth (expected) |
|---|---|---|---|---|
| Actionable Mutation Panel | MiSeq Micro v2 | 300 cycle | 19 | 500x* |
| Actionable Mutation Panel | MiSeq v2 | 500 cycle | 72 | 500x* |
| Actionable Mutation Panel | MiSeq v3 | 300 cycle | 120 | 500x* |
| Actionable Mutation Panel | MiSeq v2 | 500 cycle | 2 | 20,000x** |
| Actionable Mutation Panel | MiSeq v3 | 300 cycle | 3 | 20,000x** |
| Actionable Mutation Panel | NextSeq | 300 cycle mid output | 19 | 20,000x** |
| Actionable Mutation Panel | NextSeq | 300 cycle high output | 64 | 20,000x** |
| Actionable Mutation Panel | NovaSeq SP | 300 cycle | 120 | 20,000x** |
*gDNA/FFPE/FF
** Liquid biopsy ctDNA
For Research Use Only. Not for use in diagnostic procedures.
See our customer publications
Product support
- For access to the BED files for this panel design, please visit My Nonacus.
- FASTQ files, for example data sets, are available on request, please email support@nonacus.com or complete our support request form.
